United States securities and exchange commission logo





                             January 10, 2024

       Peter Maag, Ph.D.
       Chief Executive Officer
       Kyverna Therapeutics, Inc.
       5980 Horton St., STE 550
       Emeryville, CA 94608

                                                        Re: Kyverna
Therapeutics, Inc.
                                                            Amendment No. 3 to
Draft Registration Statement on Form S-1
                                                            Submitted January
8, 2024
                                                            CIK No. 0001994702

       Dear Peter Maag:

            We have reviewed your amended draft registration statement and have
the following
       comments.

              Please respond to this letter by providing the requested
information and either submitting
       an amended draft registration statement or publicly filing your
registration statement on
       EDGAR. If you do not believe a comment applies to your facts and
circumstances or do not
       believe an amendment is appropriate, please tell us why in your
response.

               After reviewing the information you provide in response to this
letter and your amended
       draft registration statement or filed registration statement, we may
have additional comments.

       Amendment No. 3 to Draft Registration Statement on Form S-1 submitted
January 8, 2024

       Prospectus Summary
       Our pipeline and programs, page 3

   1.                                                   We note your response
to prior comment 2 and reissue in part. Please revise your pipeline
                                                        tables here and
elsewhere to enlarge the footnotes so they are legible.
       Principal Stockholders, page 202

   2.                                                   Please revise footnote
1 to include disclosure of the natural person or persons who have
                                                        voting and investment
control of the shares held by the entity listed in the table.
 Peter Maag, Ph.D.
FirstName  LastNamePeter
Kyverna Therapeutics, Inc.Maag, Ph.D.
Comapany
January 10,NameKyverna
            2024         Therapeutics, Inc.
January
Page  2 10, 2024 Page 2
FirstName LastName
       Please contact Jenn Do at 202-551-3743 or Vanessa Robertson at
202-551-3649 if you
have questions regarding comments on the financial statements and related
matters. Please
contact Daniel Crawford at 202-551-7767 or Tim Buchmiller at 202-551-3635 with
any other
questions.



                                                         Sincerely,

                                                         Division of
Corporation Finance
                                                         Office of Life
Sciences
cc:      Jeffrey T. Hartlin, Esq.